BioSpace News Archive

Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa Labs”) today announced the pricing of an underwritten public offering of 600,000 shares of its common stock at a public offering price of $225.00 per share for gross proceeds of approximately $135 million before deducting underwriting discounts and commissions and other estimated offering expenses.

Lyvgen, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, announces that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada.

OnLume Inc., a Madison, Wisconsin-based medical imaging company with unique technology for improving precision in the operating room, has announced the appointment of James A. Bowman as Chief Executive Officer.

Atomic Blue’s high-performance UV-C germicidal light that has been approved by the U.S. Food and Drug Administration.

Castellum, Inc. (OTC: ONOV) announces the completion of its 2019 financial audit. RSM US LLC performed the audit, and Castellum received a “clean” opinion with no going concern qualification

Vivera Pharmaceuticals, Inc. a California -based pharmaceutical company focused on putting patients first, has announced the filing of two new patents with the United States Patent and Trademark Office. These patents are related to the Company’s current line of antibodies testing offerings. When approved, Vivera’s patents will

Company to Scale Capabilities and Reach as Need for Real-Time Notifications About Patients’ Care Encounters Becomes Federally Mandated [09-June-2020] BOSTON , June 9, 2020 /PRNewswire/ -- PatientPing , the nation’s leading care collaboration and e-notifications platform, today announced that it has raised $60 million in Series C funding to fuel expansion to new g

Applied BioMath announced they have been awarded a grant for the development of a software platform called Antibody Drug Conjugate Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualification in support of the development of Quantitative Systems Pharmacology Models for ADC projects.

Cell-Easy, a start-up based in Toulouse specialized in stem cell therapy, announces today the signature of an agreement with the University Hospital Centre in Toulouse, as well as securing the authorization to open a pharmaceutical manufacturing plant dedicated to the production of stem cells - a first in France. This follows the announcement made last December of raising 1M€ capital investment. Thanks to its inno

June 9, 2020 15:00 UTC Phase Ib study to combine UbiVac’s DRibble ® Platform Vaccine, DPV-001 with anti-OX40 (BMS-986178) and Opdivo (nivolumab) to test hypothesis that this combination will augment anticancer immunity in advanced triple negative breast cancer